

ADEMPAS (riociguat)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

- Pulmonary Arterial Hypertension (PAH) WHO Group 1

 NYHA functional class II-IV
- 2. Chronic Thromboembolic Pulmonary Hypertension (CTEPH) WHO Group 4
 - a. Persistent/recurrent
 - b. Prior surgical treatment or CTEPH is inoperable

AND ALL of the following:

- 1. NO concurrent therapy with any nitrates (in any form)
- 2. NO concurrent therapy with nitric oxide donors
- 3. NO concurrent therapy with phosphodiesterase-5 (PDE5) inhibitors
- 4. **NO** concurrent therapy with other soluble guanylate cyclase (sGC) stimulators (such as vericiguat)
- 5. Prescribed by or recommended by a cardiologist or pulmonologist
- Females of reproductive potential only: patient should have pregnancy excluded before the start of treatment with Adempas and patient will be advised to use effective contraception during treatment and for one month after the last dose
- 7. Female patients **only**: the patient and prescriber are enrolled in the Adempas REMS program
- 8. Prescriber agrees to monitor for pulmonary edema and discontinue if confirmed

Prior - Approval Limits

Duration 2 years

Prior – Approval Renewal Requirements

Age 18 years of age or older



ADEMPAS (riociguat)

Diagnoses

Patient must have **ONE** of the following:

- 1. Pulmonary Arterial Hypertension (PAH) WHO Group 1
- 2. Chronic Thromboembolic Pulmonary Hypertension(CTEPH) **WHO Group 4**

AND ALL of the following:

- 1. Symptoms have improved or stabilized
- 2. NO concurrent therapy with any nitrates (in any form)
- 3. **NO** concurrent therapy with nitric oxide donors
- 4. NO concurrent therapy with phosphodiesterase-5 (PDE5) inhibitors
- 5. **NO** concurrent therapy with other soluble guanylate cyclase (sGC) stimulators (such as vericiguat)
- 6. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment and for one month after the last dose
- 7. Prescriber agrees to monitor for pulmonary edema and discontinue if confirmed

Prior – Approval Renewal Limits

Same as above